Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
暂无分享,去创建一个
D. Spaeth | I. Treilleux | T. Bachelot | M. Arnedos | J. Ferrero | E. Pujade-Lauraine | A. Lortholary | C. Lévy | E. Legouffe | C. Cropet | S. Abadie-Lacourtoisie | J. Eymard | Q. Wang | A. Bourcier
[1] S. Mader,et al. LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer , 2014, International journal of cancer.
[2] C. Lefebvre,et al. Abstract S6-07: Genomic characterisation of metastatic samples from breast cancer patients using next generation sequencing , 2013 .
[3] T. Petit,et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study , 2013, Targeted Oncology.
[4] I. Treilleux,et al. Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK‐2206 with an aromatase inhibitor , 2013, International journal of cancer.
[5] I. Treilleux,et al. Activation of rapid oestrogen signalling in aggressive human breast cancers , 2012, EMBO molecular medicine.
[6] I. Ray-Coquard,et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[8] R. Kurzrock,et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Piccart,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.
[10] R. Naumann. The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer. , 2011, Gynecologic oncology.
[11] Sean E. Egan,et al. Elevated PI3K signaling drives multiple Breast Cancer subtypes , 2011, Oncotarget.
[12] B. Hennessy,et al. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. , 2011, The Journal of clinical investigation.
[13] G. Mills,et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. , 2010, The Journal of clinical investigation.
[14] Paul Ellis,et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.
[15] T. O'reilly,et al. Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals. , 2010, Translational oncology.
[16] Robert L. Sutherland,et al. Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.
[17] W. Gerald,et al. PIK3CA Mutation Associates with Improved Outcome in Breast Cancer , 2009, Clinical Cancer Research.
[18] Jeffrey A. Engelman,et al. Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.
[19] R. Memmott,et al. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. , 2009, Cellular signalling.
[20] P. Pandolfi,et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.
[21] M. Sanchez-Cespedes. A role for LKB1 gene in human cancer beyond the Peutz–Jeghers syndrome , 2007, Oncogene.
[22] A. Marchetti,et al. Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas , 2007, Clinical Cancer Research.
[23] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[24] Paul Tempst,et al. Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.
[25] Hanina Hibshoosh,et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.
[26] K. Inoki,et al. TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.
[27] K. Inoki,et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.
[28] M. Guo,et al. The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer , 2013, Modern Pathology.
[29] L. Liotta,et al. Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology. , 2011, Methods in molecular biology.
[30] J. Olson,et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer , 2009, Breast Cancer Research and Treatment.